Brought to you by 
Helsinn, Eisai to co-promote new CINV treatment in the US; Helsinn takes over all rights
18 Mar 2016
Executive Summary
Specialty pharmaceuticals company Helsinn Healthcare SA and Eisai Inc. are continuing an already successful relationship through the signing of a new deal involving a combination chemotherapy-induced nausea and vomiting (CINV) treatment.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Helsinn, Eisai to co-promote new CINV treatment in the US; Helsinn takes over all rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice